3Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson' s disease. N Engl J Med, 1993, 328 : 176-183.
4Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson' s disease. Mov Disord, 2008, 24:562-571.
5Bonuccelli U, Pavese N. Role of dopamine agonists in Parkinson' s disease : an update. Expert Rev Neurother, 2007, 7 : 1391-1399.
6Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 2002, 59 : 1541-1550.
7Albin RL, Frey KA. Initial agonist treatment of Parkinson disease : a critique. Neurology, 2003, 60 : 390-394.
8Olanow W, Schapira AH, Rascol O. Continuous dopamine- receptor stimulation in early Parkinson' s disease. Trends Neurosci, 2000, 23 ( 10 Suppl) : Sl17-126.
9Olanow CW, Watts RL, Koller WC. An algorithm ( decision tree) for the management of Parkinson' s disease ( 2001 ) : treatment guidelines. Neurology, 2001,56 ( 11 Suppl 5 ) : S1-S88.
10Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson' s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I : early (uncomplicated) Parkinson' s disease. Eur J Neurol, 2006, 13 : 1170-1185.
